Ask AI
Back Back
Gray Areas of First line PBC Therapy
Shedding Light on the Gray Areas of First-line PBC Therapy: Assessing Treatment Response

Released: March 04, 2026

Robert Wong
Robert Wong, MD, MS, FACG, FAASLD
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Timely assessment is key to properly monitoring treatment response to first-line UDCA for PBC. Guidelines suggest assessment at 12 months post treatment initiation, but emerging data support a 6-month assessment.
  • The goal of first-line treatment is to achieve an adequate response, defined as ALP <1.67x ULN, but emerging data suggest that complete normalization of ALP is associated with improved outcomes, especially for patients at risk for more advanced disease.

Individualizing Treatment Goals and Therapy Escalation
First-line treatment goals and escalation to second-line therapy are a little bit of a gray area in primary biliary cholangitis (PBC). The key to individualizing treatment goals is first understanding the overarching goal of first-line treatment. Historically, the goal of first-line PBC treatment was achieving an adequate biochemical response, defined as alkaline phosphatase (ALP) levels of <1.67 times the upper limit of normal (ULN). However, more recent data suggest that lower ALP translates into improved outcomes. I think this emerging data implies that we should be aiming for complete normalization of ALP. This is particularly relevant for patients with risk factors for more advanced disease.

When individualizing treatment response goals, I consider a couple factors. First is the individual patient factor, namely, what is the patient's risk of disease progression and decompensation? For patients who have risk factors for advanced disease and advanced fibrosis, I tend to be more aggressive with attempting to achieve ALP normalization and improving ALP beyond the traditional 1.67x ULN threshold.

The second factor I take into consideration is the patient’s disease trajectory. What improvements has the patient achieved compared to baseline? For example, if a patient had an ALP of 5x ULN before treatment initiation, and that decreased to 2x ULN after first-line treatment, I would give them some more time on UDCA. Despite not achieving ALP <1.67x ULN, I would not pull the trigger too quickly on escalating to second-line treatment, as their disease trajectory is improving. In contrast, consider someone who started with ALP 5x ULN and has only improved to ALP 3x ULN at 1 year or even 6 months post treatment. To me, this trajectory predicts a lower likelihood of achieving adequate treatment response, and this patient is someone who might benefit from earlier addition of second-line therapy.

A common misconception is that as long as ALP has improved, it is okay to continue on first-line treatment in the hopes that ALP will decline further towards normalization of ALP. This can potentially lead to waiting too long to escalate treatment. For example, someone may start with an ALP of 3x ULN, which decreases to 1.8x ULN with first-line treatment. However, the key here is not to be too complacent, especially if your patient has risk factors for advanced disease and advanced fibrosis. That decrease in ALP is an improvement, but there are emerging data that suggest achieving complete normalization of ALP may provide even better protection against disease progression.

Other Mistakes to Avoid With First-line Therapy
A key mistake that I often see, and one that I used to make myself, is waiting too long to assess treatment response and delaying escalation to second-line therapy. The current society guidelines recommend assessing treatment response at 12 months and escalating treatment if adequate response is not achieved, but sometimes people with ALP ≥1.67x ULN remain on first-line therapy even beyond 12 months.

In those who are not responding, the first consideration is whether the dose of UDCA is appropriate and if the patient is adherent to treatment. Dosing of UDCA should be weight based, so it is important to routinely assess whether the dosing of UDCA is appropriate and whether adjustment is needed based on your patient’s weight. It is also not uncommon for patients to take their medication inconsistently, resulting in subtherapeutic doses. Hence, in addition to ensuring adequate dosing, it is also important to routinely assess whether patients are taking UDCA consistently, and if not, try to help understand and address any barriers that may be contributing. Both of these factors are important in the context of assessing treatment response before escalation of therapy.

Aside from appropriate dosing and consistent adherence, when patients do not have an adequate response to UDCA, it is important to assess other possible factors. For example, considering the possibility of comorbidities or overlap syndromes with other autoimmune liver diseases, such as autoimmune hepatitis, is critical. The presence of overlap syndrome requires a different management approach than someone with PBC only.

Even when second-line therapy is appropriate, some people may be hesitant to start treatment with the available FDA-approved PPAR agonists elafibranor and seladelpar due to a lack of familiarity with these therapies or their mechanism of action, or potential concerns about safety in patients with chronic liver diseases. There may also be hesitance due to the recent withdrawal of obeticholic acid from the market. However, these PPAR agonist therapies have a different mechanism of action from obeticholic acid, and existing data from both clinical trials and real-world data demonstrate an acceptable safety profile for both of these therapies.

Another relatively common misconception in PBC management is not being aggressive enough with treatment escalation for patients with advanced disease. Remember that without appropriate treatment, patients with PBC can progress to advanced fibrosis pretty quickly, and can ultimately develop cirrhosis, hepatocellular carcinoma, decompensation, and require liver transplantation. For example, someone with F3 liver fibrosis progresses much faster than someone with F0 or F1 fibrosis.

The key take-home point is that among patients who have advanced disease or risk factors for more rapid disease progression, timely assessment of treatment response and consistent monitoring are critical. We must not lose sight of our treatment goals, and we cannot let patients linger on inadequate treatment by delaying treatment escalation and ALP normalization.

Your Thoughts
In your practice, how do you decide when to continue first-line therapy vs escalation to second-line therapy for patients with PBC? Leave a comment to join the discussion!

Continue